Stem Cells SpinWAR:SCS 25 PS Ratio is 200.00 as of Jul. 03, 2026, which is 245% above its 10-year median of 58.00. GuruFocus rates WAR:SCS with a GF Score™ of 25/100 and a GF Value™ of zł0.10 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 933 Biotechnology companies, Stem Cells Spin ranks worse than 89.5% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Stem Cells Spin's share price is zł0.40.
Stem Cells Spin's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was zł0.00. Hence, Stem Cells Spin's PS Ratio for today is 200.00.
The historical rank and industry rank for Stem Cells Spin's PS Ratio or its related term are showing as below:
WAR:SCS'
s PS Ratio Range Over the Past 10 Years
Min: 6.67 Med: 58 Max: 333.33
Current: 200
During the past 13 years, Stem Cells Spin's highest PS Ratio was 333.33. The lowest was 6.67. And the median was 58.00.
WAR:SCS's PS Ratio is ranked worse than 89.5% of 933
companies
in the Biotechnology industry
Industry Median: 9.64
vs WAR:SCS: 200.00
Stem Cells Spin SA revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of Stem Cells Spin was 100.00% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -30.70% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -30.40% per year.
During the past 10 years, the average Revenue per Share Growth Rate was -32.20% per year.
During the past 13 years, Stem Cells Spin's highest 3-Year average Revenue per Share Growth Rate was 75.50% per year. The lowest was -57.50% per year. And the median was -9.60% per year.
Back to Basics: PS Ratio
Stem Cells Spin (WAR:SCS) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Stem Cells Spin PS Ratio Related Terms
Stem Cells Spin PS Ratio Historical Data
* Premium members only.
The historical data trend for Stem Cells Spin's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Stem Cells Spin's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Stem Cells Spin PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Stem Cells Spin's PS Ratio distribution charts can be found below:
* The bar in red indicates where Stem Cells Spin's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Stem Cells Spin's Share Price of today is zł0.40. Stem Cells Spin's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was zł0.00.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Stem Cells Spin (WAR:SCS) has a PS Ratio of 200.00 as of Jul. 03, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Stem Cells Spin and its competitors. This is 245% above median its historical median of 58.00. Over the past decade, Stem Cells Spin's PS Ratio has ranged from 6.67 to 333.33. According to the industry distribution chart, Stem Cells Spin ranks #835 out of 933 companies in the Biotechnology industry, placing it in the top 89.5%.
Is Stem Cells Spin's PS Ratio too high?
Stem Cells Spin's current PS Ratio of 200.00 is 245% above median its 10-year median of 58.00. Over the past 10 years, this metric has ranged from a low of 6.67 to a high of 333.33. The Biotechnology industry median PS Ratio is 9.64. Stem Cells Spin's value of 200.00 is 1974.7% above this industry median. Based on the distribution chart, Stem Cells Spin ranks #835 out of 933 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Stem Cells Spin has a GF Score™ of 25/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Stem Cells Spin's PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Stem Cells Spin ranks #835 out of 933 companies for PS Ratio. This places Stem Cells Spin in the lower half of its industry. The industry median PS Ratio is 9.64. Stem Cells Spin's value of 200.00 is 1974.7% above this benchmark. Historically, Stem Cells Spin's own PS Ratio has ranged from 6.67 to 333.33 over the past decade. While the company's 10-year median is 58.00 vs. the industry median of 9.64, Stem Cells Spin has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.64, based on 933 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Stem Cells Spin's current PS Ratio of 200.00 is 1974.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Stem Cells Spin and its competitors. For the Biotechnology industry, the median PS Ratio is 9.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Stem Cells Spin's current PS Ratio is 200.00, which is 245% above median its own 10-year median of 58.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Stem Cells Spin stock overvalued right now?
Based on GuruFocus' analysis, Stem Cells Spin (WAR:SCS) is currently considered Significantly Overvalued. The stock's GF Value™ is zł0.10, compared to a current price of zł0.40 — trading 300% above its estimated fair value. The current PS Ratio is 200.00, which is 245% above median its 10-year median of 58.00 and 1974.7% above the Biotechnology industry median of 9.64. Stem Cells Spin's overall GF Score™ is 25/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Stem Cells Spin (WAR:SCS), the current PS Ratio is 200.00 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Stem Cells Spin (WAR:SCS) Overvalued in 2026?
Based on GuruFocus' analysis, Stem Cells Spin stock appears to be overvalued.
The current stock price of zł0.40 is trading 300% above its estimated GF Value™ of zł0.10.
GuruFocus considers Stem Cells Spin to be Significantly Overvalued.
Key valuation signals for WAR:SCS:
PS Ratio: 200.00 (245% above median its 10-year median of 58.00)
GF Value™: zł0.10 vs. price of zł0.40 (300% above fair value)
Industry Position: 1974.7% above the Biotechnology median (#835 of 933)
No single metric tells the full story. See the WAR:SCS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Stem Cells Spin SA is a biotechnology company. The company is engaged in the development, production, marketing, and sale of natural regenerative products for the dermocosmetic and veterinary care markets, as well as applications for the human and veterinary medical industry. Its products include NHAC Biocervin MIC-1, Revitacell, PRS MIC-1, and Velvetyna.
25GF Score
Get the complete analysis for WAR:SCS
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:SCS has been successfully added to your 
